Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mucic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mucic Acid SCHEMBL5312196 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL15895451 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5496 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5497 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL18871641 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL77363 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL19695496 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL3514596 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL17594183 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5901 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4516784-A1 | SURFACE ACTIVE ALDARIC ACID DERIVATIVES | Coöperatie Koninklijke Cosun U.A. (NL) | 2025-03-05 | — | — | EP | claimed |
| EP-4259832-A1 | PROCESS FOR DELIMING OF HIDES, SKINS OR PELTS | Stahl International B.V. (NL) | 2023-10-18 | — | — | EP | claimed |
| EP-4182034-A1 | PRODUCTS FOR TREATING KERATINOUS FIBERS, CONTAINING COMPLEXING AGENT AND AMINO ACID AND/OR PROTEIN HYDROLYSATE | Henkel AG & Co. KGaA (DE) | 2023-05-24 | — | — | EP | claimed |
| CN-114788791-A | Compositions and methods for improving the appearance of skin | 宝洁公司 | 2022-07-26 | — | — | CN | claimed |
| WO-2022124892-A1 | PROCESS FOR DELIMING OF HIDES, SKINS OR PELTS | STAHL INTERNATIONAL B.V. (NL) | 2022-06-16 | — | — | WO | claimed |
| EP-4720196-A1 | PURPURIN ANALOGS FOR USE IN PHOTODYNAMIC THERAPY | RMW Cho Group Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025263641-A1 | COMPOSITION COMPRISING GLYCOLIPID, CATIONIC POLYMER AND (POLY)HYDROXY ACID | L'OREAL (FR) | 2025-12-26 | — | — | WO | disclosed |
| EP-4626901-A2 | NOVEL CHLORIN E6 ANALOGUES | RMW Cho Group Limited (HK) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626894-A1 | PHYLLOCHLORIN ANALOGUES SUITABLE FOR USE IN PHOTODYNAMIC THERAPY (PDT) | RMW Cho Group Limited (HK) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626900-A1 | PORPHYRIN AND PHOSPHONIUM-PORPHYRIN BASED COMPOUNDS FOR PHOTODYNAMIC THERAPY AND DIAGNOSTICS | RMW Cho Group Limited (HK) | 2025-10-08 | — | — | EP | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20250177533-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | Invion Limited (AU) | 2025-06-05 | — | — | US | disclosed |
| US-6627061-B2 | Converting a variety of salt streams into relatively pure acids and alkali products; multicompartment cell separated by membranes, a direct current source which splits the salt into acid and base; nanofilters and ion exchange membrane | ARCHER-DANIELS-MIDLAND COMPANY | 2003-09-30 | — | — | US | disclosed |
| US-20010040093-A1 | Apparatus and process for electrodialysis of salts | ARCHER DANIELS MIDLAND COMPANY | 2001-11-15 | — | — | US | disclosed |
| US-6294066-B1 | ADJUSTING FEED STREAM OF SALT; FEED STREAM OF LIQUID INTO BASIC CONTAINER, ACIDIFY FLUID, CYCLE FLUID THROUGH BASIC CONTAINER, DISCHARGE AND ANALYZE STREAM | ARCHER DANIELS MIDLAND COMPANY | 2001-09-25 | — | — | US | disclosed |
| US-6224731-B1 | PASSING DIRECT CURRENT TO CAUSE ACIDIFICATION; ION EXCHANGING, DESALTING, NANOFILTRATION | ARCHER DANIELS MIDLAND COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-6221225-B1 | ACIDIFICATION, REMOVAL OF SOLIDS, FEEDING INTO COMPARTMENT THAT HAS BIPOLAR MEMBRANE | ARCHER DANIELS MIDLAND COMPANY | 2001-04-24 | — | — | US | disclosed |
| EP-0213591-B1 | PROCESS FOR THE MANUFACTURE OF KETO GULONIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 1992-03-25 | — | — | EP | disclosed |
| EP-0213591-A3 | PROCESS FOR THE MANUFACTURE OF KETO GULONIC ACID | — | 1988-10-05 | — | — | EP | disclosed |
| EP-0213591-A2 | Process for the manufacture of keto gulonic acid | F. HOFFMANN-LA ROCHE AG (CH) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177533-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | PPOX, PPIF, ALAD | TSHR 4639/4885PDE4A 2422/4885CYP2C9 1272/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TSHR 3394/4885PDE4A 983/4885CYP2C9 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.